BRAFV600E and KIT immunoexpression in early-stage melanoma^*

Abstract:

Melanoma is widely known as the most lethal skin cancer. Specific tumor-related mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease. The current search for biomarkers in early-stage melanomas is a high-priority challenge for physicians and researchers. We aimed to assess the immunoexpression of BRAFV600E and KIT in a case series consisting of 44 early-stage melanomas. Formalin-fixed paraffin-embedded samples were systematically evaluated using a semi-quantitative method based on scores of percentage and intensity for immunostained tumor cells. We observed significant concordance between BRAFV600E and KIT immunoexpression in thin invasive melanomas. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early-stage melanomas.

Keywords:
Biomarkers, pharmacological; Early diagnosis; Melanoma

INTRODUCTION

Cutaneous melanoma (CM) is the world’s most lethal type of skin cancer.¹ In Brazil, estimates indicate 6,260 new cases in 2018, most of which in the southernmost states.² Mortality can be significantly reduced if diagnosis and treatment are properly performed during initial phases of the disease.³

The tumor may arise de novo or from preexisting or atypical nevi.⁴ It is usually related to intermittent sun exposure and/or family history.⁴ Early-stage melanomas can be divided into melanoma in situ (MIS) and thin invasive melanoma (TM). MIS is the first stage of histologically detectable malignant melanocytic lesion and is characterized by lentiginous proliferation of atypical melanocytes.⁵ TM is defined as invasive disease with thickness less than 1.0 millimeter.⁶

Biologically, CM is a complex disease influenced by genetic and environmental factors. Stepwise acquisition of mutations leads to activation of oncogenes and inactivation of tumor suppressor genes.⁴ Constitutive activation of the mitogen-activated protein kinase (MAPK) pathway represents a crucial pathogenic mechanism in several types of cancer. ⁷ Murine sarcoma viral oncogene homolog B (BRAF) gene plays a major role in the regulation of MAPK pathway. Activating BRAF mutations occur in 40-50% of CM.⁸BRAF^V600E is the most common mutation and represents about 90% of BRAF mutations.⁸ KIT proto-oncogene (KIT) encodes a homonymous tyrosine-kinase known to activate several signaling pathways, including the MAPK and phosphoinositide-3 kinase (PI3K) pathways. It has been suggested that KIT plays a role in the early pathogenesis of CM.⁹

We assessed the immunoexpression of BRAF^V600E and KIT in a case series of early-stage skin melanomas and discussed our results in light of the current literature.

MATERIAL AND METHODS

This retrospective study was based on formalin-fixed paraffin-embedded samples obtained from the archives of a private dermatopathology laboratory in São Paulo, Brazil. Inclusion criteria: (1) early-stage melanoma diagnosis (MIS or TM); (2) paraffin block available; and (3) sufficient amount of tumor tissue.

Immunohistochemical assays were performed in 3-micrometer-thick whole tissue sections. Immunolabelling was scored based on percentage: absent (0), 1-10% (1), 11-50% (2), and greater than 50% (3); and intensity: absent (0), weak (1), moderate (2) and strong (3). Final score was obtained from the sum of both parameters. A positive score was defined as greater than or equal to 3. All slides were reviewed and interpreted by pathologists.

Cohen’s kappa agreement test was used to study concordance between BRAF^V600E and KIT immunoexpression. The study was approved by the Institutional Review Board of Universidade Federal de São Paulo under case review CAAE 30466114.9.0000.55050.

RESULTS

Table 1 summarizes the clinicopathological features. Among 44 patients with early-stage CM, there were 25 women and 19 men. Mean age at diagnosis was 54 years, ranging from 23 to 92 years. Information on age was missing for one patient (case no. 6). Nineteen patients (43.1%) presented tumors located on the trunk, 12 (27.2%) on the upper extremities, and seven (15.9%) on the lower extremities. Tumor location was not available for six cases (numbers 6, 8, 9, 30, 32, and 42).

Table 1
Clinical and pathological results

	TM subgroup	MIS subgroup	Total
Number of cases (%)	35 (79.5%)	9 (20.5%)	44 (100%)
Mean age (range)	66,1 years (46-90)	51,1 years (23-92)	54 years (23-92)
Sex ratio	1.5F: 1M	1F: 1.25M	1.3F: 1M
Anatomic location (%)	Trunk (45%)	Trunk and upper limbs (66%)	Trunk (43%)
Mean Breslow thickness (range)	0.48 mm (0.20-0.83)	Not applicable	30/35 cases (85.7%) < 0.76 mm

Our early-melanoma series consisted of 35 cases of TM (79.5%) and 9 cases of MIS (20.5%). In the invasive tumors, mean Breslow thickness was 0.48 millimeters, ranging from 0.20 to 0.83 millimeters. Thirty out of 35 TM (85.7%) showed Breslow thickness less than 0.76 millimeters.

Table 2 shows the detailed immunohistochemical data. Thirty-one out of 44 cases (70.5%) expressed KIT protein. Twenty out of 40 cases (50.0%) showed anomalous expression of BRAF^V600E mutated protein. Figures 1 and 2 show representative cases. We found significant concordance (k=0.429) between KIT and BRAF^V600E immunoexpression in the TM subgroup.

Table 2
Immunohistochemical results

	VE1-positive	KIT-positive
TM subgroup	17/32 (53.1%)	23/35 (65.7%)
MIS subgroup	03/08 (37.5%)	08/09 (88.8%)
Total	20/40 (50%)	31/44 (70.4%)

Figure 1
Melanoma in situ, KIT-positive. Atypical melanocytes dis played in a lentiginous pattern showing immunolabeling for KIT

Figure 2
Melanoma in situ, VE1-positive. The lentiginous component of this VE1-positive lesion extends into the distal segment of an ec crine duct

DISCUSSION

In recent decades, public awareness of sun damage and its harmful cumulative effects on the human skin has contributed to a significant increase in earlier detection of CM. Early-stage disease is potentially curable with local surgical resection, while thick tumors are much more likely to behave aggressively.³ Efficient markers with major prognostic significance remain to be defined.

Several intracellular signaling pathways have been implicated in melanoma genesis and progression.⁴ MAPK and PI3K pathways are among the most critical ones.⁴BRAF and KIT mutations are regarded as primary oncogenic events in tumorigenesis, occurring in different subtypes of melanoma, cutaneous or otherwise.⁴

Based on the recently published molecular classification, BRAF-related tumors represent the largest genomic subgroup.⁸ Among the hot-spot mutations for this subgroup, BRAF^V600E is the most frequent.³ Its detection has become clinically relevant after the development of BRAF and MEK inhibitors.¹⁰BRAF^V600E -mutant early-stage melanomas are strongly associated with poorer specific survival when compared to BRAF^V600E -wild type tumors.¹¹ However, its detection does not mean malignancy, since it can also be found in melanocytic nevi.¹²

Besides playing a major role in melanocyte survival, growth, differentiation, and migration, it has been suggested that KIT mutations are related to tumor progression of early disease.¹³ According to Posch et al., abnormal KIT signaling in melanoma induces to horizontal spread from the main lesion into the surrounding healthy skin.¹³ Authors further advocate that pharmacological inhibition of KIT-mutant cells might represent a potential strategy to reduce migratory activity, local recurrence, and disease spread.¹³

In this study, we found concomitant immunoexpression of BRAF^V600E and KIT proteins mainly in thin invasive melanomas in a case series consisting exclusively of early-stage tumors. As previously reported by Bastian, BRAF^V600E and KIT mutations are considered primary oncogenic events in the initiation of melanocytic neoplasia.⁴ Our findings also agree with those of Montagnani et al., who demonstrated that several point mutations such as BRAF^V600E and KIT occur early during melanoma development, whereas somatic copy number alterations tend to emerge over the course of tumor progression.¹⁴ The molecular mechanisms involved in such associations remain to be elucidated. According to Neiswender et al., a key possibility is that KIT can activate signaling through wild-type RAF proteins, thus interfering with BRAF^V600E -driven melanoma formation.¹⁵ Thereby, KIT inactivating mutations acquired along tumor progression would facilitate the fast-track proliferative pathway promoted by BRAF^V600E.¹⁵

The present study is not free of limitations. We consider the lack of molecular genomic assessment, the small sample size, and the retrospective approach without follow-up data as the most relevant ones. The high cost of molecular methods and insufficient amount of available tumor tissue were major hurdles for us. Nevertheless, our results obtained from a previously unpublished case series consisting exclusively of early-stage tumors help further characterize and elucidate melanoma emergence and progression in the Brazilian population.

Briefly, we described the frequency of BRAF^V600E and KIT immunoexpression in an early-stage melanoma series and observed significant concordance between BRAF^V600E and KIT labeling in the TM subgroup. Our findings corroborate previous evidence showing abnormal expression of proteins associated with MAPK intracellular signaling pathway in early tumors.

• *
  Study conducted at the Department of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
• Financial support: None.

ACKNOWLEDGMENTS

The authors wish to thank Dr. Andréa Cristina de Moraes Malinverni for her support in revising the manuscript.

REFERENCES

• ¹
  Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3:233-45.
• ²
  Inca.gov.br [Internet]. Tipos de câncer. Pele melanoma [cited 2018 Mar 04]. Available from: www.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/pele_melanoma
  » www.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/pele_melanoma
• ³
  Rajkumar S, Watson IR. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. Br J Cancer. 2016;115:145-55.
• ⁴
  Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239- 71.
• ⁵
  Joyce KM, Joyce CW, Jones DM, Donnellan P, Hussey AJ, Regan PJ, et al. An assessment of histological margins and recurrence of melanoma in situ. Plast Reconstr Surg Glob Open. 2015;3:e301.
• ⁶
  Mihic-Probst D, Shea C, Duncan L, de la Fouchardiere A, Landman G, Landsberg J, et al. Update on Thin Melanoma: Outcome of an International Workshop. Adv Anat Pathol. 2016;23:24-9.
• ⁷
  Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, et al. BRAF inhibitors: Resistance and the promise of combination treatments for melanoma. Oncotarget. 2017;8:78174-92.
• ⁸
  Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-96.
• ⁹
  Ecsedi S, Hernandez-Vargas H, Lima SC, Vizkeleti L, Toth R, Lazar V, et al. DNA methylation characteristics of primary melanomas with distinct biological behaviour. PLoS One. 2014;9:e96612.
• ¹⁰
  Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
• ¹¹
  Mar VJ, Liu W, Devitt B, Wong SQ, Dobrovic A, McArthur GA, et al. The role of BRAF mutations in primary melanoma growth rate and survival. Br J Dermatol. 2015;173:76-82.
• ¹²
  Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16:345-58.
• ¹³
  Posch C, Moslehi H, Sanlorenzo M, Green G, Vujic I, Panzer-Grümayer R, et al. Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo. Oncotarget. 2016;7:45916-25.
• ¹⁴
  Montagnani V, Benelli M, Apollo A, Pescucci C, Licastro D, Urso C, et al. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget. 2016;7:30365-78.
• ¹⁵
  Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK et al. KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling. Cancer Res. 2017;77:5820-30.

Publication Dates

• Publication in this collection
  17 Oct 2019
• Date of issue
  Jul-Aug 2019

History

• Received
  04 Apr 2018
• Accepted
  27 June 2018